Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

High frequency of tumours in Mulibrey nanism

View through CrossRef
Abstract Mulibrey nanism (MUL) is a monogenic disorder with prenatal‐onset growth failure, typical clinical characteristics, cardiopathy and tendency for a metabolic syndrome. It is caused by recessive mutations in the TRIM37 gene encoding for the peroxisomal TRIM37 protein with ubiquitin‐ligase activity. In this work, the frequency and pathology of malignant and benign tumours were analysed in a national cohort of 89 Finnish MUL patients aged 0.7–76 years. The subjects had a clinical and radiological evaluation, and histological and immunohistocemical analyses on specimens obtained from biopsy, surgery or autopsy, were performed. The results show that the MUL patients have disturbed architecture with ectopic tissues and a high frequency of both benign and malignant tumours detectable in several internal organs. A total of 210 tumorous lesions were detected in 66/89 patients (74%). Fifteen malignancies occurred in 13 patients (15%), seven of them in the kidney (five Wilms' tumours), three in the thyroid gland, two gynaecological cancers, one gastrointestinal carcinoid tumour, one neuropituitary Langerhans cell histiocytosis and one case of acute lymphoblastic leukaemia (ALL). Tumours detected by radiology in the liver and other organs mainly comprised strongly dilated blood vessels (peliosis), vascularized cysts and nodular lesions. The lesions showed strong expression of the endothelial cell markers CD34 and CD31 as well as the myocyte marker α‐smooth muscle actin (α‐SMA). Our findings show that MUL is associated with frequent malignant tumours and benign adenomatous and vascular lesions, as well as disturbed organ development. Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Title: High frequency of tumours in Mulibrey nanism
Description:
Abstract Mulibrey nanism (MUL) is a monogenic disorder with prenatal‐onset growth failure, typical clinical characteristics, cardiopathy and tendency for a metabolic syndrome.
It is caused by recessive mutations in the TRIM37 gene encoding for the peroxisomal TRIM37 protein with ubiquitin‐ligase activity.
In this work, the frequency and pathology of malignant and benign tumours were analysed in a national cohort of 89 Finnish MUL patients aged 0.
7–76 years.
The subjects had a clinical and radiological evaluation, and histological and immunohistocemical analyses on specimens obtained from biopsy, surgery or autopsy, were performed.
The results show that the MUL patients have disturbed architecture with ectopic tissues and a high frequency of both benign and malignant tumours detectable in several internal organs.
A total of 210 tumorous lesions were detected in 66/89 patients (74%).
Fifteen malignancies occurred in 13 patients (15%), seven of them in the kidney (five Wilms' tumours), three in the thyroid gland, two gynaecological cancers, one gastrointestinal carcinoid tumour, one neuropituitary Langerhans cell histiocytosis and one case of acute lymphoblastic leukaemia (ALL).
Tumours detected by radiology in the liver and other organs mainly comprised strongly dilated blood vessels (peliosis), vascularized cysts and nodular lesions.
The lesions showed strong expression of the endothelial cell markers CD34 and CD31 as well as the myocyte marker α‐smooth muscle actin (α‐SMA).
Our findings show that MUL is associated with frequent malignant tumours and benign adenomatous and vascular lesions, as well as disturbed organ development.
Copyright © 2009 Pathological Society of Great Britain and Ireland.
Published by John Wiley & Sons, Ltd.

Related Results

TRIMming down to TRIM37: Relevance to Inflammation, Cardiovascular Disorders, and Cancer in MULIBREY Nanism
TRIMming down to TRIM37: Relevance to Inflammation, Cardiovascular Disorders, and Cancer in MULIBREY Nanism
TRIpartite motif (TRIM) proteins are part of the largest subfamilies of E3 ligases that mediate the transfer of ubiquitin to substrate target proteins. In this review, we focus on ...
Pulmonary carcinoid tumours
Pulmonary carcinoid tumours
Key pointsPulmonary carcinoid tumours account for 2% of all lung tumours, with an increase in incidence due to more accurate diagnostic techniques.Carcinoid tumours are relatively ...
A Clinicopathological Study of Parotid Gland Tumours
A Clinicopathological Study of Parotid Gland Tumours
Abstract Background: The parotid gland is the largest salivary gland. Pleomorphic adenoma (PA) is the most common tumour found in the parotid gla...
Histomorphological Study of Renal Tumours – A Single Centre Experience
Histomorphological Study of Renal Tumours – A Single Centre Experience
BACKGROUND Renal tumours encompass a wide spectrum as distinct entities both in adults and in children. Renal cell carcinomas constitute majority of all renal neoplasms. Proper typ...
Demography and Histopathological presentations of oral and maxillo-facial region tumours in Jamshoro, Pakistan.
Demography and Histopathological presentations of oral and maxillo-facial region tumours in Jamshoro, Pakistan.
Introduction: Oral and Pharyngeal cancers are the sixth most common cancer globally. In developing countries, the annual incidence of oral cancer is around 275,000 cases while 130,...
Histopathologic Characteristics of Childhood Malignant Tumours in a Referral Medical Centre in Nigeria
Histopathologic Characteristics of Childhood Malignant Tumours in a Referral Medical Centre in Nigeria
Background: Diseases of children in most developing countries revolve commonly around infectious disorders and malnutrition. However, other conditions including neoplastic diseases...
Bromodeoxyuridine Labelling of Transitional Cell Carcinoma of the Bladder—an Index of Recurrence?
Bromodeoxyuridine Labelling of Transitional Cell Carcinoma of the Bladder—an Index of Recurrence?
Summary— Nineteen patients with newly diagnosed transitional cell carcinoma of the bladder consented to receive an intravenous bolus of bromodeoxyuridine (BrdUrd) 3 to 6 h prior t...

Back to Top